FHTX FY 2023 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M+77.6% YoY

Gross Profit

$34M100.0% margin

Operating Income

-$108M-315.9% margin

Net Income

-$98M-288.2% margin

EPS (Diluted)

$-2.34

Cash Flow

Operating Cash Flow

-$118M

Free Cash Flow

-$119M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$286M

Total Liabilities

$363M

Stockholders' Equity

-$77M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$19M	+77.6%
Gross Profit	$34M	$19M	+77.6%
Operating Income	-$108M	-$117M	+7.9%
Net Income	-$98M	-$109M	+9.6%